A 6-Year Follow-Up of a Randomized Prospective Trial Comparing Methimazole Treatment With or Without Exogenous L-Thyroxine in Chinese Patients With Graves' Disease | oneGRAVESvoice

welcome to oneGRAVESvoice

- a positively charged Graves' disease and thyroid eye disease community.
  • join today!
Scientific Articles

A 6-Year Follow-Up of a Randomized Prospective Trial Comparing Methimazole Treatment With or Without Exogenous L-Thyroxine in Chinese Patients With Graves’ Disease

key information

source: Experimental and Clinical Endocrinology & Diabetes

year: 2014

authors: Liu X, Qiang W, Liu X, Liu L, Liu S, Gao A, Gao S, Shi B

summary/abstract:

Objective:
Antithyroid drug therapy is one of the main medical treatments for Graves’ disease. There have been conflicting reports as to whether the addition of exogenous L-thyroxine improves remission rates more than antithyroid drugs alone. This randomized, controlled and prospective clinical trial was undertaken to investigate the long-term outcome of methimazole treatment with or without exogenous L-thyroxine in Chinese patients.

Methods:
145 patients with Graves’ disease were randomly divided into 3 groups and all patients initially received 30 mg of methimazole daily for at least 1 month and then followed the titration -regimen with or without L-thyroxine: group 1 (30 mg→20 mg→15 mg→10 mg→5 mg); group 2 (30 mg→20 mg→15 mg→10 mg+L-thyroxine→5 mg+L-thyroxine); group 3 (30 mg→20 mg→15 mg→10 mg+L-thyroxine→5 mg+L-thyroxine→2.5 mg+L-thyroxine). The drug therapy was discontinued after 5 months of the final dose.

Results:
16 out of 46 patients in group 1 (34.8%), 12 out of 47 in group 2 (25.5%) and 16 out of 52 in group 3 (30.8%) had a recurrence of Graves’ disease within 6-year follow-up after drug withdrawal. Survival Analysis showed no significant differences in the remission rates between any 2 groups, despite the remission rates in group 2 and 3 were slightly higher than that in group 1.

Conclusions:
The addition of L-thyroxine to methimazole treatment in patients with Graves’ disease neither improves nor prevents the remission or recurrence of Graves’ disease in China.

organization: First Affiliated Hospital of Xi'an Jiaotong University Health Science Center, China

DOI: 10.1055/s-0034-1377045